Hyperion DeFi (HYPD) Q3 2024 earnings summary

Executive summary

• Significant progress in transforming into a leader in topical ophthalmic medications using Optejet technology, with commercial launches of MydCombi and clobetasol, and a pipeline led by MicroPine for pediatric myopia.

• Advanced Phase 3 CHAPERONE study of MicroPine for pediatric progressive myopia, with interim analysis planned and potential entry into a multi-billion-dollar market.

• Expanded manufacturing capabilities, including registration batch manufacturing for Gen-2 Optejet and FDA approval for MydCombi facility.

• Entered strategic partnerships and licensing agreements for dry eye disease, targeting a $5 billion global market and expanding international reach.

• Board leadership transition and appointment of new CFO, with ongoing efforts to strengthen management and capital markets expertise.

Financial highlights

• Net loss for Q3 2024 was $7.9 million ($0.11 per share), compared to $7.3 million ($0.18 per share) in Q3 2023; nine-month net loss was $29.9 million.

• Gross loss for Q3 2024 was $131,000, mainly due to inventory write-downs related to MydCombi and Gen 1 device.

• Q3 2024 revenue was $2,000, with nine-month revenue of $29,243, reflecting early-stage commercialization.

• Unrestricted cash and cash equivalents at September 30, 2024, were $7.2 million, down from $14.8 million at year-end 2023.

• Working capital deficit of $4.1 million and accumulated deficit of $175.4 million as of September 30, 2024.

Outlook and guidance

• Anticipating Phase III CHAPERONE trial data readout for MicroPine in Q4 2024, with potential NDA filing as early as the first half of 2026 if results are positive.

• Substantial doubt exists about ability to continue as a going concern without additional capital; evaluating options to secure long-term financing.

• May need to curtail R&D or reduce costs if unable to secure funding; ongoing evaluation of capital raising options.

• Sales force targeting expansion of MydCombi offices and expecting increased reorders to drive revenue.